The Canadian Press on MSN1d
TPH saw ‘many deviations’ at gynecologist’s clinic with potential HIV, hepatitis exposure
Toronto Public Health says it observed “many deviations from best practices” during an inspection at the gynecologist's ...
MIT Technology Review2d
This annual shot might protect against HIV infections
Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.
Health and Me on MSN1d
Yearly Jab For HIV Protection Is Now Almost Here
A yearly injection such as Lenacapavir could help overcome barriers to PrEP accessibility by increasing its uptake and making ...
STAT3d
HIV self-testing is easy, effective — and underutilized
HIV self-testing remains underutilized among not only the general public, but especially people who use drugs.
Becker's Hospital Review2d
Baystate hospital alerts patients of possible infection exposure
Baystate Wing Hospital in Palmer, Mass., has contacted an unknown number of patients who may have been exposed to hepatitis or HIV due to a potential sterilization issue during surgeries performed ...
The Canadian Press on MSN5d
Potential HIV, hepatitis exposure at Toronto gynecology clinic has patients worried
The letter said patients who received endometrial biopsies, IUD insertions or had cervical growths removed at the clinic ...
STAT4d
Gilead data suggest once-yearly shot of PrEP drug blocks HIV infection
Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...
The Lancet4d
The potential for annual long-acting HIV pre-exposure prophylaxis
Pre-exposure prophylaxis (PrEP) is the advent of antiretroviral treatment use for people at increased risk of acquiring HIV-1 ...
HIV prevention medication ‘could one day be a yearly jab’ – study suggests
An annual jab to protect against HIV “shows potential”, according to an early study. Millions of people around the world are ...
Study examines a novel way to bring addiction care and HIV prevention to people who inject drugs
Researchers from the HIV Prevention Trials Network (HPTN) have presented results from the HPTN 094 ("INTEGRA") study at the ...
Applied Clinical Trials Online3d
Phase I Trial Supports Development of Once-Yearly Lenacapavir as Long-Acting HIV PrEP Option
Phase I trial results show the potential of once-yearly lenacapavir as a long-acting PrEP option for HIV, supporting further ...